CN113797310B - Pet joint health care preparation and preparation method and application thereof - Google Patents
Pet joint health care preparation and preparation method and application thereof Download PDFInfo
- Publication number
- CN113797310B CN113797310B CN202010539789.3A CN202010539789A CN113797310B CN 113797310 B CN113797310 B CN 113797310B CN 202010539789 A CN202010539789 A CN 202010539789A CN 113797310 B CN113797310 B CN 113797310B
- Authority
- CN
- China
- Prior art keywords
- weight
- health care
- parts
- powder
- joint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 230000037231 joint health Effects 0.000 title claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 51
- 230000036541 health Effects 0.000 claims abstract description 33
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 22
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960002442 glucosamine Drugs 0.000 claims abstract description 22
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 19
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 19
- 239000012528 membrane Substances 0.000 claims abstract description 19
- 235000013601 eggs Nutrition 0.000 claims abstract description 18
- 239000000796 flavoring agent Substances 0.000 claims abstract description 17
- 229920001184 polypeptide Polymers 0.000 claims abstract description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 17
- 235000019634 flavors Nutrition 0.000 claims abstract description 14
- 102000002322 Egg Proteins Human genes 0.000 claims abstract description 13
- 108010000912 Egg Proteins Proteins 0.000 claims abstract description 13
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 12
- 239000011707 mineral Substances 0.000 claims abstract description 12
- 150000007524 organic acids Chemical class 0.000 claims abstract description 12
- 229920002261 Corn starch Polymers 0.000 claims abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 10
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 10
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 10
- 239000008120 corn starch Substances 0.000 claims abstract description 10
- 210000002969 egg yolk Anatomy 0.000 claims abstract description 10
- 239000008103 glucose Substances 0.000 claims abstract description 10
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 10
- 235000013336 milk Nutrition 0.000 claims abstract description 10
- 239000008267 milk Substances 0.000 claims abstract description 10
- 210000004080 milk Anatomy 0.000 claims abstract description 10
- 235000013345 egg yolk Nutrition 0.000 claims abstract description 7
- 239000000654 additive Substances 0.000 claims abstract description 4
- 230000000996 additive effect Effects 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 23
- 238000009472 formulation Methods 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 20
- 238000011049 filling Methods 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 17
- 230000001954 sterilising effect Effects 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 238000007873 sieving Methods 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 11
- 235000010755 mineral Nutrition 0.000 claims description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- 241000287828 Gallus gallus Species 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 210000004185 liver Anatomy 0.000 claims description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 6
- 239000012752 auxiliary agent Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 4
- 239000001527 calcium lactate Substances 0.000 claims description 4
- 229960002401 calcium lactate Drugs 0.000 claims description 4
- 235000011086 calcium lactate Nutrition 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 239000004310 lactic acid Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 210000000845 cartilage Anatomy 0.000 abstract description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 31
- 210000001503 joint Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 210000000988 bone and bone Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 210000000629 knee joint Anatomy 0.000 description 5
- 210000002414 leg Anatomy 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 210000001188 articular cartilage Anatomy 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 208000030175 lameness Diseases 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 241000282465 Canis Species 0.000 description 3
- 208000012659 Joint disease Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000021050 feed intake Nutrition 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000001050 lubricating effect Effects 0.000 description 3
- 230000006996 mental state Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229920002567 Chondroitin Polymers 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 206010073767 Developmental hip dysplasia Diseases 0.000 description 2
- 208000007446 Hip Dislocation Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 239000004227 calcium gluconate Substances 0.000 description 2
- 229960004494 calcium gluconate Drugs 0.000 description 2
- 235000013927 calcium gluconate Nutrition 0.000 description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- KXLUWEYBZBGJRZ-POEOZHCLSA-N Canin Chemical compound O([C@H]12)[C@]1([C@](CC[C@H]1C(=C)C(=O)O[C@@H]11)(C)O)[C@@H]1[C@@]1(C)[C@@H]2O1 KXLUWEYBZBGJRZ-POEOZHCLSA-N 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- GPFVKTQSZOQXLY-UHFFFAOYSA-N Chrysartemin A Natural products CC1(O)C2OC2C34OC3(C)CC5C(CC14)OC(=O)C5=C GPFVKTQSZOQXLY-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000001726 jatropha manihot extract Substances 0.000 description 1
- 208000018934 joint symptom Diseases 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229940072543 manganese gluconate Drugs 0.000 description 1
- 239000011683 manganese gluconate Substances 0.000 description 1
- 235000014012 manganese gluconate Nutrition 0.000 description 1
- OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 229940106668 yucca extract Drugs 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/20—Animal feeding-stuffs from material of animal origin
- A23K10/26—Animal feeding-stuffs from material of animal origin from waste material, e.g. feathers, bones or skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/24—Compounds of alkaline earth metals, e.g. magnesium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K40/00—Shaping or working-up of animal feeding-stuffs
- A23K40/25—Shaping or working-up of animal feeding-stuffs by extrusion
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Physiology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Birds (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Fodder In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a pet joint health care preparation, which is characterized by comprising the following components: (1) minerals; (2) an organic acid; (3) a flavor phagostimulant; (4) A carrier selected from the group consisting of glucose, maltodextrin, corn starch, milk powder and egg yolk powder; (5) A functional component selected from the group consisting of egg membrane polypeptide powder, chondroitin sulfate, and glucosamine. The invention also provides a preparation method of the health care preparation and application of the health care preparation as an additive for pet joint health care. The joint health care preparation can be used for daily joint health care of pets, increases joint sliding amount, strengthens cartilage, enables inflamed or damaged joints to quickly detumescence and recover to a normal state, and opens a new idea for joint health care of pets.
Description
Technical Field
The invention relates to the technical field of pet health care, in particular to a pet joint health care preparation and a preparation method and application thereof
Background
During the growth of pets, joint problems cannot be ignored. While many pet owners are equivalent to joint care for calcium supplement, they are not. The discomfort of joints can cause inconvenient actions of pets such as dogs and the like and lose the daily activity.
The pet can leave the joint at one time, so that the life of the pet is influenced by the quality of the joint. Hip dysplasia, bone degeneration, osteoporosis, various arthritis, and the like in pets are the most common joint problems. However, these conditions are mainly caused by:
excessive obesity results in lack of exercise: the pet is excessively obese due to factors such as pet variety, eating habits, lack of exercise, sterilization operation, age and the like, and the excessive obesity of the pet can burden various tissues and organs of the body, such as the joints, so that the probability of causing bone problems and arthritis is higher, and the postoperative recovery is more difficult.
Excessive exertion caused by excessive exercise: the normal articular cartilage is used as a 'shock absorber' and can play a role in buffering and lubricating when the joint moves, if a pet moves excessively for a long time, the articular cartilage can be quickly worn, and the excessive wear of the articular cartilage can easily cause joint diseases.
Age-induced bone aging: the physical function of pets gradually entering the elderly will also gradually deteriorate, and the joints will generally gradually age and become stiff.
Congenital inheritance: congenital factors are mainly genetic defects, such as hip dysplasia, which is one of the most common joint diseases in dogs. The incidence of severe pets is high, so that pets suffering from the disease should be strictly prohibited from growing during breeding.
Difficulty in recovery after joint surgery: pets are not easy to limit the movement completely after joint operation, so that the operation is often accompanied by some movement, and the joint recovery after operation is slow.
CN201517333742. X discloses a pet joint health care agent and a preparation method thereof, wherein the pet joint health care agent comprises the following components: chondroitin sulfate, glucosamine hydrochloride, dimethyl sulfone, collagen, vitamin D3, vitamin E, zinc gluconate, manganese gluconate, calcium gluconate, yucca extract, flavoring agent and adjuvants; the flavoring agent is chicken liver powder or beef powder. The auxiliary materials are starch and lactose, and the weight ratio of the starch is as follows: lactose is 4:1. The health care agent for the joints of the pets adopts glucosamine, which is considered to be an important precursor of biological synthesis of cartilage tissues, and the lack of the glucosamine in the bodies can directly lead to the occurrence of various bone joint diseases; the health care agent also adopts glucosamine, which is considered to be a natural substance extracted from marine organism crustaceans, and can become the most effective and non-side effect drug after being taken by combining with chondroitin as a nutritional agent; the pure glucosamine and chondroitin combination can only play a role in relieving inflammation. In contrast, the health care agent of the patent application not only relieves inflammation, but also is supplemented with trace elements, vitamins, collagen, plant extracts and other nutrient substances required by healthy growth of animal bones, so that the quick recovery of the animal bones is promoted, and meanwhile, the flavoring agent (chicken liver powder and beef powder) is added, so that the palatability of the product is improved.
Aiming at the health care problem of the joints of the pets, the invention provides a completely different formula, and opens a completely different new idea for the health care of the joints of the pets.
Disclosure of Invention
In order to solve the health care problem of the joints of the pets, the invention provides a health care preparation for the joints of the pets, which comprises the following components: (1) minerals; (2) an organic acid; (3) a flavor phagostimulant; (4) A carrier selected from the group consisting of glucose, maltodextrin, corn starch, milk powder and egg yolk powder; (5) A functional component selected from the group consisting of egg membrane polypeptide powder, chondroitin sulfate, and glucosamine.
The present invention provides in a second aspect a method of preparing a health care formulation as described in the first aspect of the present application, the method comprising the steps of:
(1) Mixing: sieving mineral substances, organic acid, flavor phagostimulant, carrier, chondroitin sulfate and glucosamine which are optionally used as functional components, mixing uniformly, and adding water to mix into paste;
(2) And (3) drying: drying the paste and cooling to room temperature;
(3) Addition of other components: adding egg membrane polypeptide powder and tabletting auxiliary agent which can be selected as functional components, uniformly mixing and sieving to obtain a mixed material;
(4) Tabletting: taking out the mixed materials, and tabletting by a tablet press to obtain the health care preparation.
In a third aspect, the present invention provides the use of a health care formulation according to the first aspect of the present invention as an additive for joint health in pets.
The invention provides a brand new pet joint health care preparation, which contains functional components such as chondroitin sulfate, glucosamine, egg membrane polypeptide powder and the like, can be used for daily joint health care of pets, increases joint sliding amount, strengthens cartilage and opens a new idea for joint health care of pets.
Drawings
Fig. 1 shows joint status of dogs fed a health care formulation according to an embodiment of the present invention in the first week (a), the second week (B), and the third week (C). The left and right images show the joint photographs taken at different angles, respectively.
Detailed Description
The present invention will be described in detail with reference to specific examples. The following examples will assist those skilled in the art in further understanding the present invention, but are not intended to limit the invention in any way. It should be noted that variations and modifications could be made by those skilled in the art without departing from the inventive concept. These are all within the scope of the present invention.
The invention provides a pet joint health care preparation, which comprises the following components: (1) minerals; (2) an organic acid; (3) a flavor phagostimulant; (4) A carrier selected from the group consisting of glucose, maltodextrin, corn starch, milk powder and egg yolk powder; (5) A functional component selected from the group consisting of egg membrane polypeptide powder, chondroitin sulfate, and glucosamine.
In the formulation of the present invention, chondroitin sulfate is an enzyme capable of absorbing moisture into the molecule of proteoglycan chondroitin sulfate to thicken cartilage and increase the amount of sliding fluid in joints, inhibiting destruction of cartilage such as collagenase, elastase, cathepsin and the like. The glucosamine is used as an important raw material for forming the lubricating substance between the articular cartilage tissue and the joint, can provide the functions of joint lubrication and glucosamine protection, can stimulate cartilage cells to generate more collagen, glycoprotein and glycosaminoglycan, and can enable the joint to absorb more lubricating liquid so as to ensure the joint softness. The egg membrane polypeptide is extracted from fibrous membrane between egg membrane, i.e. eggshell and egg white, and clings to nipple layer of eggshell. The inventor discovers that the health care preparation containing functional components such as chondroitin sulfate, glucosamine, egg membrane polypeptide and the like has remarkable effect on joint health care in the formula system.
In some preferred embodiments, the health care formulation consists of the following components: (1) minerals; (2) an organic acid; (3) a flavor phagostimulant; (4) A carrier selected from the group consisting of glucose, maltodextrin, corn starch, milk powder and egg yolk powder; (5) A functional component selected from the group consisting of egg membrane polypeptide powder, chondroitin sulfate, and glucosamine. In other preferred embodiments, the carrier consists of glucose, maltodextrin, corn starch, milk powder and egg yolk powder. In other preferred embodiments, the functional component consists of egg membrane polypeptide powder, chondroitin sulfate, and glucosamine.
In some preferred embodiments, the mineral is 1.5 to 5 parts by weight (e.g., 2, 3, or 4 parts by weight); the organic acid is 0.02 to 0.5 parts by weight (e.g., 0.05, 0.1, 0.2, 0.3, or 0.4 parts by weight); the flavour phagostimulant is 7 to 17 parts by weight (e.g. 10 or 15 parts by weight); the carrier is 27 to 88 parts by weight (e.g., 30, 40, 50, 60, 70, or 80 parts by weight); the functional component is 4.51 to 23 parts by weight (e.g., 5, 10, 15, or 20 parts by weight).
In some preferred embodiments, the mineral is calcium lactate; the organic acid is lactic acid; and/or the flavor phagostimulant is selected from the group consisting of brewer's yeast powder and chicken liver powder.
In other preferred embodiments, the flavor phagostimulant comprises brewer's yeast powder and chicken liver powder; the carrier comprises glucose, maltodextrin, corn starch, milk powder and yolk powder; and/or the functional component comprises egg membrane polypeptide powder, chondroitin sulfate and glucosamine.
In some preferred embodiments, the flavor phagostimulant consists of brewer's yeast powder and chicken liver powder. More preferably, the carrier consists of glucose, maltodextrin, corn starch, milk powder and egg yolk powder. Even more preferably, the functional component consists of egg membrane polypeptide powder, chondroitin sulfate and glucosamine.
In other preferred embodiments, the health care formulation comprises:
in other preferred embodiments, the health care formulation is a tablet and further comprises a tabletting aid selected from the group consisting of microcrystalline cellulose and magnesium stearate; preferably, the tabletting aid is from 0.5 to 4.6 parts by weight (e.g. 1, 2, 3 or 4 parts by weight).
In other preferred embodiments, the microcrystalline cellulose is 0.3 to 3.5 parts by weight (e.g., 1.0, 2, or 3 parts by weight) and the magnesium stearate is 0.2 to 1.1 parts by weight (e.g., 0.5 or 1.0 parts by weight).
The health care preparation is suitable for dogs and cats in all stages. Can be fed twice daily. Directly eating or grinding, and adding into food for feeding.
The amount of 1 g/tablet is exemplified and can be carried out according to the following table.
The present invention provides in a second aspect a method of preparing a health care formulation as described in the first aspect of the present application, the method comprising the steps of:
(1) Mixing: sieving mineral substances, organic acid, flavor phagostimulant, carrier, chondroitin sulfate and glucosamine which are optionally used as functional components, mixing uniformly, and adding water to mix into paste;
(2) And (3) drying: drying the paste and cooling to room temperature;
(3) Addition of other components: adding egg membrane polypeptide powder and tabletting auxiliary agent which can be selected as functional components, uniformly mixing and sieving to obtain a mixed material;
(4) Tabletting: taking out the mixed materials, and tabletting by a tablet press to obtain the health care preparation.
In some preferred embodiments, the method further comprises: (5) sterilizing and filling: sterilizing the health care preparation before filling, and sterilizing after filling.
In some more specific embodiments, the method comprises the steps of:
(1) Mixing: sieving mineral substances, organic acid, flavor phagostimulant, carrier, chondroitin sulfate and glucosamine which are optionally used as functional components with a 100-mesh sieve to prevent caking materials and impurities from mixing, uniformly mixing the materials after sieving, and adding a proper amount of water to fully mix into paste;
(2) And (3) drying: placing the paste into an oven for drying, wherein the drying temperature is 70 ℃, the drying time is 6 hours, and the dried material is cooled to room temperature;
(3) Addition of other components: adding egg membrane polypeptide powder and tabletting auxiliary agent which can be selected as functional components into the cooled material, fully and uniformly mixing, and sieving the uniformly mixed material with a 18-mesh screen to obtain a mixed material;
(4) Tabletting: taking out the mixed materials, tabletting by a single-punch tablet press, wherein the humidity during tabletting is less than or equal to 50%, the temperature is less than or equal to 28 ℃, and the pressure is 3.00-5.00 kg/cm 2 Tabletting to obtain tablet.
(5) And (3) sterilization: sterilizing the tablets prior to filling;
(6) And (3) filling: transferring the sterilized tablets to a filling line, and respectively filling and sealing the tablets under the condition (avoiding secondary pollution) that an air dynamic sterilizer with 2000 air volume is started for 60 minutes;
(7) Sterilizing after filling: and (3) sterilizing by a pasteurization method (70-80 ℃ for 30-40 minutes) after filling.
In a third aspect, the present invention provides the use of a health care formulation according to the first aspect of the present invention as an additive for joint health in pets. Preferably, the pet is a pet dog or a pet cat.
Examples
The invention will be further illustrated by way of examples, to which the scope of the invention is not limited. The starting materials used in the examples were all commercially available conventional starting materials unless otherwise indicated.
Preparation example
The pet joint care formulation was prepared according to the formulation shown in table I in the following manner (if a component is not present, the use of the corresponding component is omitted):
1. mixing: the preparation method comprises the steps of sieving formula amounts of calcium lactate, lactic acid or calcium gluconate, beer yeast powder, chicken liver powder, glucose, maltodextrin, milk powder, yolk powder, chondroitin sulfate (WUHan Yimeite biosciences Co., ltd.), glucosamine (WUHan Yimeite biosciences Co., ltd.) and corn starch with a 100-mesh screen to prevent caking materials and impurities from mixing, sieving, mixing the materials uniformly, and adding a proper amount of water for full mixing.
2. And (3) drying: and (3) putting the uniformly mixed materials into a baking oven for baking, wherein the baking temperature is 70 ℃, the baking time is 6 hours, and the baked materials are cooled to room temperature.
3. Adding other components: bovine collagen (WU Han dynasty's Biotechnology Co., ltd.), egg membrane polypeptide powder (Hubei Shendi Huifeng Biotechnology Co., ltd.), microcrystalline cellulose and magnesium stearate are added into the cooled material, and the mixture is fully and uniformly mixed, and the mixture is subjected to sieving with a 18-mesh sieve to obtain the finished product.
4. Tabletting: taking out the mixed materials, tabletting by a single-punch tablet press, wherein the humidity during tabletting is less than or equal to 50%, the temperature is less than or equal to 28 ℃, and the pressure is 4.00 kg/cm 2 Tabletting to obtain finished joint tablet (0.7 g/tablet) for pets.
5. And (3) sterilization: sterilizing the tablet before filling.
6. And (3) filling: the sterilized tablets are transferred to a filling line, and the two specifications of tablets are respectively filled and sealed under the condition (avoiding secondary pollution) that an air dynamic sterilizer with 2000 air quantity is started for 60 minutes.
7. Sterilizing after filling: after filling, sterilization was performed by pasteurization (75 ℃ C., 35 minutes).
Table I formulations (parts by weight) used in the various preparations
Pet joint care formulations (sometimes referred to as "inventive joint discs") were prepared according to formulations 1 to 4 in preparation examples 1 to 4, respectively.
Test example 1: joint health effect test
Animals used in the test examples: shanxi blue test beagle model beagle dogs with arthritis over 2 years of age.
The method for establishing the model of the arthritis dogs comprises the following steps: chicken egg protein solution (20 mg/ml), BCG vaccine and Freund's incomplete adjuvant (three ratio lml:2ml: lm1) were mixed and made into a mixed emulsion at 1500r/min homogenizer. 5mg egg protein was then injected into the unilateral knee joint cavity of the dog. Pathological observation shows that the diameter of the joint and the surface temperature are greatly increased on the 1 st day after the injection of the egg proteins, and the injected hind limb is in a turning state within one week.
Joint symptoms: manifesting as stiff movement, inactivity, reduced movement, local arthrocele, repeated licking of the arthrocele, painful and ill dogs after touch, difficulty standing and walking, and lifting or lameness.
Treatment protocol: the joint health care preparation prepared in the following steps of feeding basic complete dog food (ROYAL Canin Royal dog food) and practical preparation examples 1 to 4, 3 tablets each time, 2 times daily, and 24 days in feeding period. The joint site recovery was observed and the joint swelling was recorded and the results are shown in table 1 and fig. 1.
TABLE 1 results of the joint recovery state
The above table data is expressed as diseased joint circumference-initial joint circumference before injection = swelling degree at predetermined time points.
The treatment effect is as follows: the therapeutic effect is shown in Table 1. The health care preparation of preparation examples 1 to 4 was fed, and the first week, the left leg unilateral knee joint part of the dogs was obviously swollen, the dogs had lameness and had pain, and the activity was reduced. At the second week, the left leg unilateral knee joint swelling was slightly relieved, the joint circumference was reduced, and mild lameness was observed. On the third week, the left leg unilateral knee joint of dogs fed the health care formulation of preparation examples 1 to 3 still swelled, with slightly reduced joint circumference, still slightly lameness; the swelling of the knee joint on one side of the left leg of the dog fed the health care preparation of preparation example 4 is obviously relieved, the circumferences of the joints on both sides are basically recovered to be nearly consistent, the stress on the joints on both legs is uniform, and the activity is increased (see figure 1).
Test example 2: food calling test
Test animals: 14 beagle dogs over 2 years old (7 puppies, 7 puppies. Initial body weight is around 10 kg, and inter-individual differences are within 1 kg).
The test contents are as follows: once a day at 8 a.m. for a total of 3 times. The joint plates of the test group or the control group were prepared in 3 parts each of 3 plates, and 6 parts of the joint plates were randomly placed. Every two trays are placed in the same parallel area 15 cm apart. 1 dog was led to an independent experimental area each time, and the pet dogs were allowed to freely move to eat, and 14 dogs were individually selected. The number of selections of 2 articular discs was recorded. The results are shown in Table 2.
Table 2 results of taste test selection of example and comparative articular discs
Conclusion: the taste experiments of the pet joint sheets show that compared with the comparison joint sheets, the pet joint sheets prepared by the method provided by the invention are higher in each selection experiment and the final total selected times, and the pet joint sheets provided by the invention are better in feeding attraction, can promote the diet of pets, and further provide a basis for nutrition absorption of animals.
Test example 3: clinical comprehensive effect test
Experimental animals: 14 beagle dogs with similar physiological states (half of male and female, with individual differences in initial body weight within 1 kg) over 2 years old
Experimental grouping: according to the principle that the weights are similar and the male and female are half, the tests are divided into 2 groups, namely 8 test groups and 4 control groups.
Wherein the test group was fed with the basic whole canine diet and the joint patch of the present invention (3 tablets each time, 2 times daily), the control group was fed with the basic whole canine diet and the commercial control joint patch (4 tablets each time, 2 times daily), and the feeding period was 30 days.
Feeding management of tested dogs: 14 beagle dogs were kept in single cages. Body weights were weighed at day 0, 7, 14, 21, 30 at the beginning of the test. The feces are cleaned, the dog house is cleaned, the basin is cleaned and the clean drinking water is replaced every morning. Fecal status was recorded at the time of fecal cleaning. The dogs in the test group were fed 3 tablets of the invention at 8 am each day, the control group was fed 4 tablets of the commercial control joint tablet (MAG pet article jindong self-camping flagship store), and the basic whole price canine food for each dog was fed 150g at 9 am each day. And drinking water is freely taken throughout the day. The 16 pm feeding test group fed 3 of the joint sheets of the invention and the control group fed 4 of the commercial control joint sheets, and after half an hour, 200g of the basic full-price dog food was fed to each dog, and the dogs were tethered outside the house for proper exercise every day.
The feeding mode of the joint plates comprises the following steps: taking the joint slices in a clean empty basin, and directly feeding the joint slices at 8 am: 00 and 16 pm: 00. If the direct feeding is feasible, the method is used in the whole test process. If individual dogs do not eat the feed by adopting a direct feeding mode, the joint slices are crushed and then directly mixed into basic ration for feeding, and the feed is still fed for 2 times.
Detecting the index: recording the weight, observing the feeding condition, the defecation condition, the fur state and the motility every day, recording in detail, and carrying out mathematical statistical analysis on the experimental result after the experiment is finished.
Test results: the results are shown in Table 3.
Table 3 results of comparative comprehensive Effect test
Conclusion: from the above table, the overall weight change of dogs in the test group and the control group was not great, and the present joint plates were able to promote more effectively the weight gain of the test dogs in the later feeding period than the commercially available control joint plates. The bowel movement state indicates that the present joint discs are more gastrointestinal friendly than the commercially available control joint discs. The results of feed intake, hair state, mental state and the like show that the joint slice and the commercial control joint slice generally have no adverse effect on the feed intake, hair state and mental state, and the effects of the feed intake, the hair state and the mental state are not obviously different.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention, and are not limiting; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some technical features thereof can be replaced by equivalents; these modifications or substitutions do not depart from the gist of the technical solutions of the embodiments of the present invention.
Claims (7)
1. The pet joint health care preparation is characterized by comprising the following components:
(1) Calcium lactate as a mineral; (2) lactic acid as an organic acid; (3) The flavor phagostimulant consists of beer yeast powder and chicken liver powder; (4) The carrier consists of glucose, maltodextrin, corn starch, milk powder and yolk powder; (5) The functional component consists of egg membrane polypeptide powder, chondroitin sulfate and glucosamine; (6) tabletting auxiliary agent; and is also provided with
The weight portions of the components are as follows:
2 parts by weight of calcium lactate as the mineral;
lactic acid as the organic acid is 0.02 parts by weight;
9 parts by weight of chicken liver powder serving as the flavor phagostimulant and 5 parts by weight of beer yeast powder;
27 to 88 parts by weight of the carrier, and wherein 3 to 11 parts by weight of corn starch, 3 to 13 parts by weight of milk powder, 2 to 6 parts by weight of egg yolk powder, 4 to 12 parts by weight of glucose, and 15 to 46 parts by weight of maltodextrin;
1 part by weight of egg membrane polypeptide powder, 2.3 parts by weight of chondroitin sulfate and 15 parts by weight of glucosamine serving as the functional components;
the tabletting auxiliary agent is 0.5 to 4.6 parts by weight.
2. The health care formulation according to claim 1, characterized in that the health care formulation is a tablet and the tabletting aid is selected from the group consisting of microcrystalline cellulose and magnesium stearate.
3. The health care formulation according to claim 2, wherein the microcrystalline cellulose is 0.3 to 3.5 parts by weight and the magnesium stearate is 0.2 to 1.1 parts by weight.
4. A method of preparing the health care formulation of any one of claims 1 to 3, comprising the steps of:
(1) Mixing: sieving mineral substances, organic acid, flavor phagostimulant, carrier, chondroitin sulfate and glucosamine as functional components, mixing, and adding water to obtain paste;
(2) And (3) drying: drying the paste and cooling to room temperature;
(3) Addition of other components: adding egg membrane polypeptide powder and tabletting auxiliary agent as functional components, uniformly mixing and sieving to obtain a mixed material;
(4) Tabletting: taking out the mixed materials, and tabletting by a tablet press to obtain the health care preparation.
5. The method according to claim 4, wherein the method further comprises: (5) sterilizing and filling: sterilizing the health care preparation before filling, and sterilizing after filling.
6. Use of a health formulation according to any one of claims 1 to 3 for the preparation of an additive for joint health in pets.
7. The use according to claim 6, wherein the pet is a pet dog or a pet cat.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010539789.3A CN113797310B (en) | 2020-06-15 | 2020-06-15 | Pet joint health care preparation and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010539789.3A CN113797310B (en) | 2020-06-15 | 2020-06-15 | Pet joint health care preparation and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113797310A CN113797310A (en) | 2021-12-17 |
| CN113797310B true CN113797310B (en) | 2024-04-12 |
Family
ID=78892232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010539789.3A Active CN113797310B (en) | 2020-06-15 | 2020-06-15 | Pet joint health care preparation and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113797310B (en) |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916565A (en) * | 1996-03-08 | 1999-06-29 | In Clover, Inc. | Product and method for treating joint disorders in vertebrates |
| WO2000056164A1 (en) * | 1999-03-22 | 2000-09-28 | Kal Kan Foods, Inc. | Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals |
| WO2001032188A1 (en) * | 1999-11-02 | 2001-05-10 | Shawn Paul Madere | Compositions of orally administered nutritional supplements to repair articular cartilage |
| AU2005200953A1 (en) * | 1999-03-22 | 2005-03-24 | Mars, Incorporated | Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals and method of manufacturing same |
| CN101322551A (en) * | 2007-08-31 | 2008-12-17 | 辽源雷霓森药业有限公司 | Combination for increasing bone density and repairing articular cartilage |
| CN103143002A (en) * | 2013-03-29 | 2013-06-12 | 武汉中博绿亚生物科技有限公司 | Healthcare agent for pet bone joint and preparation method of healthcare agent |
| CN104188999A (en) * | 2014-08-13 | 2014-12-10 | 哈药集团制药六厂 | Composition capable of increasing bone density and improving functions of skeletons and joints and preparation method thereof |
| CN106620657A (en) * | 2015-11-02 | 2017-05-10 | 瑞普（天津）生物药业有限公司 | Healthcare agent for pet joints and preparation method thereof |
| CN108323764A (en) * | 2018-01-19 | 2018-07-27 | 湖北神地生物科技有限公司 | A method of extraction membranes of fowl eggshells polypeptide simultaneously prepares Bones and joints health products |
| CN108450652A (en) * | 2018-02-07 | 2018-08-28 | 上海宠幸宠物用品有限公司 | A kind of health food and preparation method thereof for repairing pet dog joint injury |
| CN109984269A (en) * | 2017-12-29 | 2019-07-09 | 瑞普（天津）生物药业有限公司 | It is a kind of with the pet nutrition cream and preparation method of replenishing the calcium and keep articulation health |
| CN110859247A (en) * | 2019-11-11 | 2020-03-06 | 深圳市红瑞生物科技有限公司 | Composition, preparation method and application thereof in preparation of medicines, health-care products and foods for treating joint diseases of pets |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6924273B2 (en) * | 2000-10-03 | 2005-08-02 | Scott W. Pierce | Chondroprotective/restorative compositions and methods of use thereof |
| US8703174B2 (en) * | 2006-09-15 | 2014-04-22 | I Did It Inc | Joint preserving nutritional vitamin, mineral and herbal pet supplement |
-
2020
- 2020-06-15 CN CN202010539789.3A patent/CN113797310B/en active Active
Patent Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916565A (en) * | 1996-03-08 | 1999-06-29 | In Clover, Inc. | Product and method for treating joint disorders in vertebrates |
| WO2000056164A1 (en) * | 1999-03-22 | 2000-09-28 | Kal Kan Foods, Inc. | Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals |
| AU2005200953A1 (en) * | 1999-03-22 | 2005-03-24 | Mars, Incorporated | Pet food for maintenance of joint health and alleviation of arthritic symptoms in companion animals and method of manufacturing same |
| WO2001032188A1 (en) * | 1999-11-02 | 2001-05-10 | Shawn Paul Madere | Compositions of orally administered nutritional supplements to repair articular cartilage |
| CN101322551A (en) * | 2007-08-31 | 2008-12-17 | 辽源雷霓森药业有限公司 | Combination for increasing bone density and repairing articular cartilage |
| CN103143002A (en) * | 2013-03-29 | 2013-06-12 | 武汉中博绿亚生物科技有限公司 | Healthcare agent for pet bone joint and preparation method of healthcare agent |
| CN104188999A (en) * | 2014-08-13 | 2014-12-10 | 哈药集团制药六厂 | Composition capable of increasing bone density and improving functions of skeletons and joints and preparation method thereof |
| CN106620657A (en) * | 2015-11-02 | 2017-05-10 | 瑞普（天津）生物药业有限公司 | Healthcare agent for pet joints and preparation method thereof |
| CN109984269A (en) * | 2017-12-29 | 2019-07-09 | 瑞普（天津）生物药业有限公司 | It is a kind of with the pet nutrition cream and preparation method of replenishing the calcium and keep articulation health |
| CN108323764A (en) * | 2018-01-19 | 2018-07-27 | 湖北神地生物科技有限公司 | A method of extraction membranes of fowl eggshells polypeptide simultaneously prepares Bones and joints health products |
| CN108450652A (en) * | 2018-02-07 | 2018-08-28 | 上海宠幸宠物用品有限公司 | A kind of health food and preparation method thereof for repairing pet dog joint injury |
| CN110859247A (en) * | 2019-11-11 | 2020-03-06 | 深圳市红瑞生物科技有限公司 | Composition, preparation method and application thereof in preparation of medicines, health-care products and foods for treating joint diseases of pets |
Non-Patent Citations (4)
| Title |
|---|
| Chondroitin sulphate: A complex molecule with potential impacts on a wide range of biological systems;Robert M. Lauder;《Complementary Therapies in Medicine》;第17卷;第56-62页 * |
| 浅谈关节保护剂在犬骨关节炎上应用;刘晓琳;邹连生;刘卫;;养犬(03);第1页 * |
| 盛华刚.《中药药剂学课堂笔记》.同济大学出版社,2018,第194-195页. * |
| 补肾壮筋汤联合盐酸氨基葡萄糖对大鼠膝软骨细胞 增殖及凋亡影响的研究;李宇;《中国骨质疏松杂志》;第26卷(第1期);第25-30页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113797310A (en) | 2021-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104396869B (en) | A kind of mountain swine rearing method | |
| US7485325B2 (en) | Animal food supplement compositions and methods of use | |
| Davidson et al. | Nutrition and welfare | |
| Souza et al. | Lactation performance and diet digestibility of dairy cows in response to the supplementation of Bacillus subtilis spores | |
| JPH082268B2 (en) | Dietary products containing methylsulfonylmethane and their use | |
| US20110251153A1 (en) | Prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria | |
| JP2005151928A (en) | Additive for feed | |
| Johnson-Delaney | Ferret nutrition | |
| KR101059672B1 (en) | Duck breeding method capable of spawning duck eggs containing sulfur and duck eggs produced by the breeding method | |
| CN114601065A (en) | Pet hair-removing food and preparation method thereof | |
| CN104381604A (en) | Moringa oleifera feed additive | |
| CN114223788A (en) | Complex enzyme preparation for effectively removing hair bulbs in pet bodies and application thereof | |
| CN103689226A (en) | Mulberry leaf powder feed | |
| WO2005032268A9 (en) | Animal/marine feed supplement in the improvement of feed efficiency | |
| CN108902039A (en) | A kind of high Humid Area improves the fattening cultivation method of beef cattle meat | |
| JP2009523453A (en) | Morinda citrifolia (Yaeyama Aoki) fortified product for administration to animals | |
| CN113797310B (en) | Pet joint health care preparation and preparation method and application thereof | |
| CN111264699A (en) | Chinese herbal medicine feed and preparation process thereof | |
| JP2009209057A (en) | Immunoactivator and its manufacturing method, and foodstuff for human being, fodder for animal or domestic animal, immunoactivator for plant, and cosmetic raw material, each comprising the immunoactivator | |
| CN107467670B (en) | Probiotic preparation and preparation method and application thereof | |
| CN110692811A (en) | Compound feed for mandarin fish culture and preparation method thereof | |
| CN109924342A (en) | A kind of mixed feed and feed addictive and preparation method thereof for reducing sow and limb hoof disease occurring | |
| KR20040069487A (en) | Feed including garlic for poultry | |
| CN109418540A (en) | A kind of livestock and poultry growth promotion composition and preparation method thereof and purposes | |
| Böhm et al. | The impact of feeding a high-fibre and high-fat concentrated diet on the recovery of horses suffering from gastric ulcers. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |